We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Interventional MRI in prostate cancer – the Nijmegen experience

Firstly, an abstract by Professor Jürgen Futterer at the Department of Medical Imaging Radboud University Nijmegen Medical Center, The Netherlands, with the title “Interventional MRI in prostate cancer – the Nijmegen experience” was presented.

In his abstract Professor Futterer concludes that “For example, MR image-guided laser ablation (MRgLA), in contrast to other ablative techniques, is fast and creates a sharply defined ablation zone and can be performed under local anesthesia in an outpatient setting. Therefore, the anticipated treatment related co-morbidities are expected to be considerably lower than those for the radical treatment options or other focal therapy strategies.”

The abstracts is published in the iMRI 2022 Abstract Book, p. 13.

MRI guided focal laser ablation (MRgFLA) for localized intermediate-risk prostate cancer – results of a phase II study

Secondly, an abstract with the title “MRI guided focal laser ablation (MRgFLA) for localized intermediate-risk prostate cancer – results of a phase II study” by the principal investigator MD Sangeet Ghai at University Health Network, Toronto, was presented sharing 24-month data from the study using CLS TRANBERG® products. The group reported that no major treatment-related adverse events has occurred. 23 of 26 sites of prostate cancer were free of disease at treatment site on 6-month biopsy and 19 of 26 sites at 24 months in the 25 participants.

The authors concluded that targeted focal therapy of intermediate-risk prostate cancer performed under MRgFLA is safe with encouraging 2 year oncological and functional outcomes.

The abstracts is published in the iMRI 2022 Abstract Book, p. 16-18.